Large deviations of cancer recurrence timing

We study large deviation events in the timing of disease recurrence. In particular, we are interested in modeling cancer treatment failure due to mutation-induced drug resistance. We first present a two-type branching process model of this phenomenon, where an initial population of cells that are sensitive to therapy can produce mutants that are resistant to the therapy. In this model, we investigate two random times, the recurrence time and the crossover time. Recurrence time is defined as the first time that the population size of mutant cells exceeds a given proportion of the initial population size of drug-sensitive cells. Crossover time is defined as the first time that the resistant cell population dominates the total population. We establish convergence in probability results for both recurrence and crossover time. We then develop expressions for the large deviations rate of early recurrence and early crossover events. We characterize how the large deviation rates and rate functions depend on the initial size of the mutant cell population. We finally look at the large deviations rate of early recurrence conditioned on the number of mutant clones present at recurrence in the special case of a deterministically decaying sensitive population. We find that if recurrence occurs before the predicted law of large numbers limit then there will likely be an increase in the number of clones present at recurrence time.

[1]  M. Sion On general minimax theorems , 1958 .

[2]  Sheldon M. Ross,et al.  Stochastic Processes , 2018, Gauge Integral Structures for Stochastic Calculus and Quantum Electrodynamics.

[3]  J. Rosenthal A First Look at Rigorous Probability Theory , 2000 .

[4]  S. Varadhan,et al.  Large deviations , 2019, Graduate Studies in Mathematics.

[5]  S. Bonin,et al.  Overview on Clinical Relevance of Intra-Tumor Heterogeneity , 2018, Front. Med..

[6]  N. Yoo,et al.  Detection of low‐level EGFR T790M mutation in lung cancer tissues , 2011, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[7]  J. Budczies,et al.  Heterogeneous expression of Wnt/β‐catenin target genes within colorectal cancer , 2007, International journal of cancer.

[8]  Mikko Alava,et al.  Branching Processes , 2009, Encyclopedia of Complexity and Systems Science.

[9]  K. Leder,et al.  Escape times for branching processes with random mutational fitness effects , 2014 .

[10]  Serik Sagitov,et al.  On the path to extinction , 2007, Proceedings of the National Academy of Sciences.

[11]  R. Durrett Branching Process Models of Cancer , 2015 .

[12]  Tibor Antal,et al.  Cancer recurrence times from a branching process model , 2019, PLoS Comput. Biol..

[13]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[14]  P. Jagers,et al.  Markovian paths to extinction , 2007, Advances in Applied Probability.

[15]  Herbert Levine,et al.  Large population solution of the stochastic Luria–Delbrück evolution model , 2013, Proceedings of the National Academy of Sciences.

[16]  Martin A Nowak,et al.  Evolution of Resistance During Clonal Expansion , 2006, Genetics.

[17]  T. Antal,et al.  Mutation frequencies in a birth–death branching process , 2017, The Annals of Applied Probability.

[18]  T. Antal,et al.  Mutant number distribution in an exponentially growing population , 2014, 1410.3307.

[19]  K. Leder,et al.  Dynamics of cancer recurrence , 2013, 1307.5179.

[20]  Marvin K. Nakayama,et al.  On finite exponential moments for branching processes and busy periods for queues , 2004, Journal of Applied Probability.

[21]  Lurias,et al.  MUTATIONS OF BACTERIA FROM VIRUS SENSITIVITY TO VIRUS RESISTANCE’-’ , 2003 .